{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T03:02:41Z","timestamp":1740106961079,"version":"3.37.3"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,9,18]],"date-time":"2024-09-18T00:00:00Z","timestamp":1726617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,9,18]],"date-time":"2024-09-18T00:00:00Z","timestamp":1726617600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100006390","name":"University of Lausanne","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100006390","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Langenbecks Arch Surg"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>Pancreatic ductal adenocarcinoma (PDAC) has been shown to have a lower incidence in patients with blood group O. It is currently uncertain if patients with group O have a better prognosis after pancreatectomy. This study assessed the overall survival (OS) and disease-free survival (DFS) of PDAC patients who underwent upfront pancreatoduodenectomy based on ABO blood groups.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>A cross-sectional study was performed including patients from two university centers. All consecutive head PDAC patients who underwent upfront pancreatoduodenectomy from 2000 to 2016 were included. OS and DFS were compared between blood groups A, B, AB, and O using Kaplan-Meier curves and log-rank tests.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>A total of 438 patients were included (215 women, median age 67). Pre- and intraoperative details were comparable between all subgroups. Median OS did not differ between the four blood groups (A: 23 months, 95%\u00a0CI 18\u201328; B: 32, 95%\u00a0CI 20\u201344; AB: 37, 95%\u00a0CI 18\u201356 and O: 26, 95%\u00a0CI 20\u201332, <jats:italic>p<\/jats:italic>\u2009=\u20090.192). Median DFS were also similar (A: 19 months, 95%\u00a0CI 15\u201323; B: 26, 95%\u00a0CI 19\u201333; AB: 35, 95%\u00a0CI 15\u201355 and O: 22, 95%\u00a0CI 15\u201329, <jats:italic>p<\/jats:italic>\u2009=\u20090.441). There was no OS difference between O and non-O groups (median: 26 months, 95%\u00a0CI 20\u201333 vs. 25 months, 95%\u00a0CI 20\u201330, <jats:italic>p<\/jats:italic>\u2009=\u20090.773). On multivariable analysis blood groups were not prognostic of OS. Only lymph node involvement, tumor differentiation, and adjuvant chemotherapy were independent prognostic factors.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>OS and DFS were similar between all four blood groups after pancreatoduodenectomy. Independent predictors of OS were associated with tumor characteristics and adjuvant treatment.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00423-024-03469-8","type":"journal-article","created":{"date-parts":[[2024,9,25]],"date-time":"2024-09-25T06:05:29Z","timestamp":1727244329000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Prognostic value of ABO blood groups in upfront operated pancreatic ductal adenocarcinomas"],"prefix":"10.1007","volume":"409","author":[{"given":"Ga\u00ebtan-Romain","family":"Joliat","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ismail","family":"Labgaa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Martin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dionisios","family":"Vrochides","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Markus","family":"Sch\u00e4fer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,9,18]]},"reference":[{"key":"3469_CR1","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/S0140-6736(16)00141-0","volume":"388","author":"T Kamisawa","year":"2016","unstructured":"Kamisawa T, Wood LD, Itoi T, Takaori K (2016) Pancreatic cancer. Lancet 388:73\u201385. https:\/\/doi.org\/10.1016\/S0140-6736(16)00141-0","journal-title":"Lancet"},{"key":"3469_CR2","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1097\/SLA.0000000000004147","volume":"275","author":"O Strobel","year":"2022","unstructured":"Strobel O, Lorenz P, Hinz U et al (2022) Actual five-year Survival after Upfront Resection for pancreatic ductal adenocarcinoma: who beats the odds? Ann Surg 275:962\u2013971. https:\/\/doi.org\/10.1097\/SLA.0000000000004147","journal-title":"Ann Surg"},{"key":"3469_CR3","doi-asserted-by":"publisher","first-page":"8249","DOI":"10.1245\/s10434-021-10401-7","volume":"28","author":"G Belfiori","year":"2021","unstructured":"Belfiori G, Crippa S, Francesca A et al (2021) Long-term survivors after Upfront Resection for pancreatic ductal adenocarcinoma: an actual 5-Year analysis of Disease-Specific and Post-recurrence Survival. Ann Surg Oncol 28:8249\u20138260. https:\/\/doi.org\/10.1245\/s10434-021-10401-7","journal-title":"Ann Surg Oncol"},{"key":"3469_CR4","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1093\/jnci\/djp020","volume":"101","author":"BM Wolpin","year":"2009","unstructured":"Wolpin BM, Chan AT, Hartge P et al (2009) ABO blood group and the risk of pancreatic cancer. J Natl Cancer Inst 101:424\u2013431. https:\/\/doi.org\/10.1093\/jnci\/djp020","journal-title":"J Natl Cancer Inst"},{"key":"3469_CR5","doi-asserted-by":"publisher","first-page":"5588","DOI":"10.3748\/wjg.v16.i44.5588","volume":"16","author":"J-B Greer","year":"2010","unstructured":"Greer J-B, Yazer M-H, Raval J-S et al (2010) Significant association between ABO blood group and pancreatic cancer. World J Gastroenterol 16:5588\u20135591. https:\/\/doi.org\/10.3748\/wjg.v16.i44.5588","journal-title":"World J Gastroenterol"},{"key":"3469_CR6","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1093\/aje\/kws458","volume":"177","author":"HA Risch","year":"2013","unstructured":"Risch HA, Lu L, Wang J et al (2013) ABO blood group and risk of pancreatic cancer: a study in Shanghai and meta-analysis. Am J Epidemiol 177:1326\u20131337. https:\/\/doi.org\/10.1093\/aje\/kws458","journal-title":"Am J Epidemiol"},{"key":"3469_CR7","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1038\/ng.429","volume":"41","author":"L Amundadottir","year":"2009","unstructured":"Amundadottir L, Kraft P, Stolzenberg-Solomon RZ et al (2009) Genome-wide association study identifies variants in the ABO locus associated with susceptibility to pancreatic cancer. Nat Genet 41:986\u2013990. https:\/\/doi.org\/10.1038\/ng.429","journal-title":"Nat Genet"},{"key":"3469_CR8","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1111\/j.1349-7006.2011.01907.x","volume":"102","author":"M Nakao","year":"2011","unstructured":"Nakao M, Matsuo K, Hosono S et al (2011) ABO blood group alleles and the risk of pancreatic cancer in a Japanese population. Cancer Sci 102:1076\u20131080. https:\/\/doi.org\/10.1111\/j.1349-7006.2011.01907.x","journal-title":"Cancer Sci"},{"key":"3469_CR9","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1016\/j.hpb.2020.01.004","volume":"22","author":"H Williams","year":"2020","unstructured":"Williams H, Jajja MR, Hashmi SS et al (2020) Association of ABO blood group with survival following pancreatoduodenectomy for pancreatic ductal adenocarcinoma. HPB (Oxford) 22:1557\u20131562. https:\/\/doi.org\/10.1016\/j.hpb.2020.01.004","journal-title":"HPB (Oxford)"},{"key":"3469_CR10","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1097\/SLA.0000000000002345","volume":"268","author":"IE Demir","year":"2018","unstructured":"Demir IE, J\u00e4ger C, Schlitter AM et al (2018) R0 Versus R1 resection matters after Pancreaticoduodenectomy, and less after distal or total pancreatectomy for pancreatic Cancer. Ann Surg 268:1058\u20131068. https:\/\/doi.org\/10.1097\/SLA.0000000000002345","journal-title":"Ann Surg"},{"key":"3469_CR11","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1016\/s1091-255x(00)80105-5","volume":"4","author":"TA Sohn","year":"2000","unstructured":"Sohn TA, Yeo CJ, Cameron JL et al (2000) Resected adenocarcinoma of the pancreas-616 patients: results, outcomes, and prognostic indicators. J Gastrointest Surg 4:567\u2013579. https:\/\/doi.org\/10.1016\/s1091-255x(00)80105-5","journal-title":"J Gastrointest Surg"},{"key":"3469_CR12","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1097\/01.sla.0000133083.54934.ae","volume":"240","author":"D Dindo","year":"2004","unstructured":"Dindo D, Demartines N, Clavien P-A (2004) Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg 240:205\u2013213","journal-title":"Ann Surg"},{"key":"3469_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/SLA.0b013e318296c732","volume":"258","author":"K Slankamenac","year":"2013","unstructured":"Slankamenac K, Graf R, Barkun J et al (2013) The comprehensive complication index: a novel continuous scale to measure surgical morbidity. Ann Surg 258:1\u20137. https:\/\/doi.org\/10.1097\/SLA.0b013e318296c732","journal-title":"Ann Surg"},{"key":"3469_CR14","unstructured":"Campbell F, Cairns A, Duthie F et al (2019) G091-Dataset for histopathological reporting of carcinomas of the pancreas, ampulla of Vater and common bile duct. https:\/\/www.rcpath.org\/static\/34910231-c106-4629-a2de9e9ae6f87ac1\/G091-Dataset-for-histopathological-reporting-of-carcinomas-of-the-pancreas-ampulla-of-Vater-and-common-bile-duct.pdf"},{"key":"3469_CR15","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1002\/cam4.1097","volume":"6","author":"K El Jellas","year":"2017","unstructured":"El Jellas K, Hoem D, Hagen KG et al (2017) Associations between ABO blood groups and pancreatic ductal adenocarcinoma: influence on resection status and survival. Cancer Med 6:1531\u20131540. https:\/\/doi.org\/10.1002\/cam4.1097","journal-title":"Cancer Med"},{"key":"3469_CR16","doi-asserted-by":"publisher","first-page":"e41984","DOI":"10.1371\/journal.pone.0041984","volume":"7","author":"D Wang","year":"2012","unstructured":"Wang D, Wang Z, Zhang L et al (2012) Are risk factors associated with outcomes in pancreatic cancer? PLoS ONE 7:e41984. https:\/\/doi.org\/10.1371\/journal.pone.0041984","journal-title":"PLoS ONE"},{"key":"3469_CR17","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1016\/j.hpb.2018.03.009","volume":"20","author":"K Khalil","year":"2018","unstructured":"Khalil K, Bansal S, Ayaani S et al (2018) Does blood group affect survival following pancreatoduodenectomy for periampullary malignancy? HPB (Oxford) 20:848\u2013853. https:\/\/doi.org\/10.1016\/j.hpb.2018.03.009","journal-title":"HPB (Oxford)"},{"key":"3469_CR18","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1186\/1471-2407-12-319","volume":"12","author":"NN Rahbari","year":"2012","unstructured":"Rahbari NN, Bork U, Hinz U et al (2012) AB0 blood group and prognosis in patients with pancreatic cancer. BMC Cancer 12:319. https:\/\/doi.org\/10.1186\/1471-2407-12-319","journal-title":"BMC Cancer"},{"key":"3469_CR19","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/s0304-4165(99)00183-x","volume":"1473","author":"S Hakomori","year":"1999","unstructured":"Hakomori S (1999) Antigen structure and genetic basis of histo-blood groups a, B and O: their changes associated with human cancer. Biochim Biophys Acta 1473:247\u2013266. https:\/\/doi.org\/10.1016\/s0304-4165(99)00183-x","journal-title":"Biochim Biophys Acta"},{"key":"3469_CR20","doi-asserted-by":"publisher","first-page":"5883","DOI":"10.21873\/anticanres.12931","volume":"38","author":"M Parra-Robert","year":"2018","unstructured":"Parra-Robert M, Santos VM, Canis SM et al (2018) Relationship between CA 19.9 and the Lewis phenotype: options to improve diagnostic efficiency. Anticancer Res 38:5883\u20135888. https:\/\/doi.org\/10.21873\/anticanres.12931","journal-title":"Anticancer Res"},{"key":"3469_CR21","doi-asserted-by":"publisher","first-page":"188409","DOI":"10.1016\/j.bbcan.2020.188409","volume":"1875","author":"G Luo","year":"2021","unstructured":"Luo G, Jin K, Deng S et al (2021) Roles of CA19-9 in pancreatic cancer: Biomarker, predictor and promoter. Biochim Biophys Acta Rev Cancer 1875:188409. https:\/\/doi.org\/10.1016\/j.bbcan.2020.188409","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"3469_CR22","doi-asserted-by":"publisher","first-page":"1863","DOI":"10.1093\/hmg\/ddq061","volume":"19","author":"M Barbalic","year":"2010","unstructured":"Barbalic M, Dupuis J, Dehghan A et al (2010) Large-scale genomic studies reveal central role of ABO in sP-selectin and sICAM-1 levels. Hum Mol Genet 19:1863\u20131872. https:\/\/doi.org\/10.1093\/hmg\/ddq061","journal-title":"Hum Mol Genet"},{"key":"3469_CR23","doi-asserted-by":"publisher","first-page":"e1000072","DOI":"10.1371\/journal.pgen.1000072","volume":"4","author":"D Melzer","year":"2008","unstructured":"Melzer D, Perry JRB, Hernandez D et al (2008) A genome-wide association study identifies protein quantitative trait loci (pQTLs). PLoS Genet 4:e1000072. https:\/\/doi.org\/10.1371\/journal.pgen.1000072","journal-title":"PLoS Genet"},{"key":"3469_CR24","doi-asserted-by":"publisher","first-page":"1958","DOI":"10.1161\/ATVBAHA.109.192971","volume":"29","author":"AD Paterson","year":"2009","unstructured":"Paterson AD, Lopes-Virella MF, Waggott D et al (2009) Genome-wide association identifies the ABO blood group as a major locus associated with serum levels of soluble E-selectin. Arterioscler Thromb Vasc Biol 29:1958\u20131967. https:\/\/doi.org\/10.1161\/ATVBAHA.109.192971","journal-title":"Arterioscler Thromb Vasc Biol"}],"container-title":["Langenbeck's Archives of Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00423-024-03469-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00423-024-03469-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00423-024-03469-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,25]],"date-time":"2024-09-25T21:40:35Z","timestamp":1727300435000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00423-024-03469-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,18]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["3469"],"URL":"https:\/\/doi.org\/10.1007\/s00423-024-03469-8","relation":{},"ISSN":["1435-2451"],"issn-type":[{"type":"electronic","value":"1435-2451"}],"subject":[],"published":{"date-parts":[[2024,9,18]]},"assertion":[{"value":"6 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 September 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 September 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Vaud Ethics Committee (CER-VD, 18.06.2019, n\u00b02017\u2009\u2212\u200901169).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was obtained from all individuals included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Patients signed informed consent regarding publishing their data.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"282"}}